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Highlights 
1. The spray drying process produced polymorphic transformations in (piroxicam) PXM 
2. Glucosamine (GLU) improved dissolution in spray dried samples 
3. GLU generally exhibited lower charge densities as compared to PXM 
4. GLU improved the handling of PXM as it significantly reduced its charge in all the spray dried 
formulations. 
5. Technique could be used to determine appropriate formulations that improve handling  
 
 
 
Abstract 
This work explores the use of both spray drying and D-glucosamine HCl (GLU) as a hydrophilic 
carrier to improve the dissolution rate of piroxicam (PXM) whilst investigating the electrostatic 
charges associated with the spray drying process. Spray dried PXM:GLU solid dispersions were 
prepared and characterised (XRPD, DSC, SEM). Dissolution and triboelectric charging was also 
conducted. The results showed that the spray dried PXM alone, without GLU produced some 
PXM form II (DSC results) with no enhancement in solubility relative to that of the parent PXM. 
XRPD results also showed the spray drying process to decrease the crystallinity of GLU and 
solid dispersions produced. The presence of GLU improved the dissolution rate of PXM. Spray 
dried PXM: GLU at a ratio of 2:1 had the most improved dissolution. The spray drying process 
generally yielded PXM-GLU spherical particles of around 2.5 µm which may have 
contributed to the improved dissolution.  PXM showed a higher tendency for charging in 
comparison to the carrier GLU (- 3.8 versus 0.5 nC/g for untreated material and -7.5 versus 3.1 
nC/g for spray dried materials). Spray dried PXM and spray dried GLU demonstrated higher charge 
densities than untreated PXM and untreated GLU, respectively. Regardless of PXM:GLU ratio, all 
spray dried PXM:GLU solid dispersions showed a negligible charge density (net-CMR: 0.1 – 0.3 
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nC/g). Spray drying of PXM:GLU solid dispersions can be used to produce formulation powders 
with practically no charge and thereby improving handling as well as dissolution behaviour of 
PXM.  
Keywords: Solid dispersions; Piroxicam; D-glucosamine HCl; Dissolution; Electrostatics; Spray 
drying. 
 
Abbreviations: GLU, D-glucosamine hydrochloride; DSC, differential scanning calorimetry; XRPD, X-ray powder 
diffraction; FTIR, Fourier transform infra-red; BCS, biopharmaceutical classification system; CBZ, carbamazepine; 
PXM, piroxicam; NSAID, non-steroidal anti-inflammatory drug; DE, dissolution efficiency; MDT, mean dissolution 
time; MDR, mean dissolution rate; ATR, attenuated total reflection; PSD, particle size distribution; USP, United States 
pharmacopoeia; PM, physical mixture. 
 
1. Introduction 
The physiochemical properties of a drug can influence the choice of dosage form in which it is 
delivered. Properties such as stability, pKa, partition coefficient and salt forms are all taken into 
consideration during pre-formulation studies [1]. In addition, it is important to assess the aqueous 
solubility, dissolution rate and intestinal permeability of a drug. These three factors have been used 
to classify drugs in the Biopharmaceutical Classification System (BCS) into four different classes  
[2]. BCS class II drugs are characterized by high membrane permeability but low aqueous solubility 
therefore; there is a low drug concentration gradient between the gut and the blood vessels limiting 
drug transport and oral bioavailability. The poor solubility of drugs has always been a major 
problem in pharmaceutical development and this problem is now more prevalent with more than 40 
% of the new chemical entities being practically insoluble in water or lipophilic in nature [3-7]. As 
dissolution rates are typically the rate-limiting step for bioavailability, especially for poorly soluble 
drugs, enhancement of solubility is vital to attaining suitable systemic concentrations for therapeutic 
effect [8]. 
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Despite the recent advances in particle engineering, one of the most common method employed to 
aid the improvement of the dissolution rate of poorly soluble drugs is particle size reduction using 
high shear milling methods [9, 10]. This enhancement of dissolution rate by size reduction is due to 
the fact that solubility of drugs in intrinsically related to particle size of the drug [7]. As the particle 
size of the drug is reduced, the surface area available for solvation also increases. Particle size 
reduction is a safe method of increasing drug dissolution without altering the chemical nature of the 
drug. However, although particle size reduction leads to an increase in the effective surface area of 
the drug available to interact with the solvent, it does not increase equilibrium solubility of the drug  
[11] unless the size of particles are reduced to below 1 micrometre [12]. In addition, micronization 
may cause agglomeration and thus may negatively impact on the solubility and bioavailability 
during the storage of the final product [13]. Moreover, milled particles usually exhibit a high level 
of electrostatic charge; such high level of charge can increase the inter-particle cohesive forces 
leading to poor product performance [14-16].  
Other methods used to improve drug solubility include complexation [17], liquisolid techniques 
[18, 19] and salt formation   [20, 21]. Several authors have classed the solid dispersion approach as 
one of the most effective method of improving dissolution of drugs [5, 8, 22]. It involves the 
dispersion of one or more active ingredients in an inert excipient or carrier, where the active 
ingredients could exist in a finely crystalline, solubilised or amorphous state [23, 24]. Solid 
dispersion also enhances the absorption and efficacy of drugs in a dosage form, despite limitations 
such as cost, scale up and physicochemical instabilities of the dispersions under normal storage 
conditions [25-27]. Al-Hamidi and co-workers have studied the rate of carbamazepine (CBZ), 
ibuprofen (IBU) and PXM (PXM) in solvent evaporated and co-ground solid dispersions [3, 22, 28, 
29]. Asare-Addo et al [8], also studied the effect of GLU on indomethacin (IND) dissolution and 
charging properties using a solvent evaporation process. All these authors showed that 
incorporation of GLU in PXM, IBU, CBZ and IND using either the solvent evaporation or grinding 
method significantly increased the dissolution rates of these drugs. They attributed the increased 
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solubility and dissolution rate of drugs observed to be due to particle size reduction to sub-micron 
levels, change in polymorphic forms and the improved wettability of the drug particle by the 
dissolved hydrophilic carrier [28, 30].  
PXM (4-hydroxy-2-methyl-N-(2-piridyl) 2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide) is one 
of the most potent non-steroidal anti-inflammatory and analgesic drugs used in treatment of various 
acute and chronic musculoskeletal and joint disorders [31]. This drug was used as the model BCS 
class II drug. In addition, GLU was the preferred hydrophilic carrier due to its popular use as a 
nutritional supplement for humans in decreasing pain and improving mobility in osteoarthritic joints 
of humans when administered orally [32, 33]. The limited solubility of PXM leads to a delayed 
onset of therapeutic effect. Oral absorption is slow and gradual with maximum absorption occurring 
3 – 5 hours after administration and a long half-life of elimination [34].  
Spray drying of poorly soluble drugs could potentially enhance their solubility [35]. The state of the 
final spray dried product depends on the nature of the drug as the process may result in the 
amorphous, partially crystalline, metastable crystal forms [36]. The ability of a pure drug substance 
to convert into its amorphous form during spray drying depends mainly on its inherent glass 
forming ability and crystallization tendency [37] and to a lesser extent on the preparation methods 
[38, 39]. In the amorphous state, the drug exhibits high levels of super-saturation in aqueous media 
compared to the crystalline drug, thereby achieving higher apparent solubility [40]. Spray drying 
works by providing a large surface area where heat transfer and atomization of the solution or 
suspension into small droplets can occur. It is also good at producing a uniform product that is 
spherical in shape [41]. By spraying the substance into a steam of hot air, the droplet will dry to 
form individual solid particles at a fast drying rate within milliseconds to a few seconds as a result 
of the high surface to volume ratio, which prevents phase separation between the drug and polymer 
components [42].  
In pharmaceutical development field, characterization of the electrostatic properties of powders has 
become a subject of extensive research [43]. Electrostatic charging within powders is generated 
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from inter-particulate contacts and collisions (particle-particle and particle-surface collisions) in a 
gaseous environment; i.e. two different materials brought to contact and then separated [44]. To 
date, there are no pharmacopoeial methods for charge characterization [45]. Although bipolar charging 
commonly takes place in industrial processes of pharmaceutical particulates [46], the most prevalent 
assessment of tribocharging is gained from the Faraday pail method, which provides only limited 
information in the form of net charge-to-mass ratio [47]. In this work, a novel instrument recently 
developed in the Wolfson Centre [48] (Figure 1a) to characterise the charge properties of the 
particulate materials under investigation in the form of charge distribution is used. The major 
advantages of this method of charge sensing include its high sensitivity (charges on the particles 
equal or more than to 30×10
-15
 C are detectable), quick measurement (< 1 min) and the lack of the 
particle flow disturbance. Kaialy et al. [16] applied the latter method to characterize the charge 
distribution of several size fractions of spray dried mannitol. In this study, the efficiency of the 
spray drying process in enhancing the dissolution rate of the PXM using GLU as a hydrophilic 
carrier is investigated. Recently, Adebisi et al (2016) [49], also utilized this methodology in 
determining the charge distribution in co-ground solid dispersions. The charging propensity of the 
solid dispersions produced as a result of the spray drying process is also assessed to determine its 
effect on the handling of these dispersions. To the best of our knowledge, there is no reported work 
that has investigated the use of GLU in spray dried solid dispersions and the charge distributions 
from resulting samples. 
 
2. Materials and Methods 
2.1. Materials 
PXM was purchased from TCI Chemicals (Japan). GLU was purchased from Sigma-Aldrich (UK). 
The solvent used (acetone) was obtained from Fischer Scientific (UK) was of analytical grade and 
was used as obtained. The dissolution medium (pH 1.2) was prepared according to the USP 2003 
method using the following materials: KCl (Sigma, UK) and concentrated HCl (Fisher, UK).  
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2.2. Preparation of PXM-GLU physical mixtures 
Physical mixtures (PM) of PXM were prepared by mixing PXM and GLU in a Turbula
®
 blender 
(Type T2 C, Switzerland) for 10 min. Different PXM:GLU ratios (2:1, 1:1 and 1:2) were prepared 
for comparison. The powders were stored in screw-capped glass vials in a desiccator at room 
temperature until required after the mixing process. 
 
2.3. Preparation of spray dried solid dispersions of drug-carrier 
The spray drier (SD-06AG laboratory spray dryer, LabPlant UK) was set up in a closed mode 
configuration with an inlet temperature of 70 °C, a feed flow rate set to 10 mL min
-1
 and a nozzle 
size of 0.5 mm. Suspensions of PXM and GLU were made at three different drug:carrier ratios: 1:1 
(Sample A) 1:2 (Sample B) and 2:1 (Sample C). When making the 1:1 ratio, 1.5 g of PXM was 
dissolved in a beaker containing 600 mL of acetone whereas 1.5 g of GLU was dissolved in a 
beaker containing 600 mL of deionised water under stirring conditions. The two solutions were then 
mixed together to form sample A. In the case of the 1:2 ratios, 1.5 g of PXM was dissolved in a 
beaker containing 600 mL of acetone and 3 g of GLU was also dissolved in a beaker containing 600 
mL of deionised water. The two solutions were mixed together and that constituted sample B. For 
the 2:1 ratio, 3 g of PXM was dissolved in a beaker containing 600 mL of acetone and 1.5 g of GLU 
was also dissolved in a beaker containing 600 mL of deionised water. The two solutions were 
mixed together to form sample C. PXM (1.5 g PXM dissolved in 600 mL acetone) and GLU (1.5 g 
GLU dissolved in 600 mL deionised water) were also spray-dried separately as control samples. 
The suspensions were under constant stirring (200 rpm) throughout the feeding process into the 
spray dryer to ensure uniformity. The solid dispersions obtained were stored in a desiccator until 
required. 
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2.4. Particle Size Analysis (PSD) 
A Sympatec laser diffraction particle size analyser (Clausthal-Zellerfeld, Germany) was used for the 
determination of the particle size distribution of the spray-dried formulations. The mean particle 
size (D10%, D50% and D90%) was calculated automatically using the software provided. The 
procedure was as follows: about 2–3 g of each sample was transferred into the funnel of the VIBRI 
(vibrator feeder). The sample container was cautiously tapped against the funnel to ensure all the 
content was transferred. A test reference measurement was performed with the HELOS sensor using 
WINDOX software followed by a standard measurement. In this technique a laser beam is passed 
through the sample, and different size particles diffract the light at different angles to produce 
a particle size distribution [3]. 
 
2.5. Scanning electron microscopy (SEM) 
Electron micrographs of PXM, spray dried PXM, GLU, spray dried GLU and all the spray 
dried solid dispersion in the various ratios were obtained using a scanning electron microscope 
(Jeol JSM-6060CV SEM) operating at 10 kV. The samples were mounted on a metal stub with 
double-sided adhesive tape and were sputter-coated with using a Quorum SC7620 Sputter Coater 
under vacuum with gold in an argon atmosphere prior to observation. Micrographs with different 
magnifications of 500x, 100x, 3000x and 5000x were taken to facilitate the study of the 
morphology of the solid dispersions. 
 
2.6. Differential scanning calorimetry (DSC) 
Samples of spray-dried solid dispersions or PM of drug:carrier (3 - 6 mg) were placed in standard 
aluminium pans (40 µL) with a vented lid. The crimped aluminium pans were heated from 20 to 
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250 °C at a scanning rate of 10 °C/min using nitrogen gas as a purge gas in a DSC 1 (Mettler-
Toledo, Switzerland). The enthalpy, onset temperatures and melting points of the samples were 
obtained using the STAR
e
 thermal analysis software. 
 
2.7. X-ray powder diffraction (XRPD) 
The untreated PXM, GLU and PXM-GLU solid dispersions were characterised by X-ray powder 
diffraction (XRPD) according to the methodology reported by Laity et al 2015 [50] using a D2 
Phaser diffractometer (Bruker AXS GmbH, Karlsruhe, Germany), with a sealed microfocus 
generator operated at 30 kV and 10 mA, producing CuKa (λX = 0.1542 nm) radiation and a Lynxeye 
‘silicon strip’ multi-angle detector. The samples were scanned in Bragg-Brantano geometry, over a 
scattering (Bragg, 2θ) angle range from 5 to 100°, in 0.02° steps at 1.5° min− 1. 
The XRPD patterns of were obtained using a Bruker D2 Phaser XRPD diffractometer. The samples 
were scanned from 5° to 10°
 
2  at a rate of 1.5° min−1. 
 
2.8. Solubility studies 
Excess amount of the powder formulations were added to glass vials containing 10 mL of buffer 
(pH 1.2). The vials were sealed and placed into a Wise Bath WSB-18, where they were agitated at 
37 °C ± 0.5 °C for 48 h. The solutions were then filtered using a 0.45  m membrane filter 
(Whatman, UK) and the filtrates were diluted with buffer (pH 1.2) before the absorbance of these 
solutions were measured using a UV spectrophotometer (UV-160, Shimadzu, Nakagyo, Japan) at 
333 nm. The drug concentration in the samples was determined by applying a calibration curve 
which had a correlation coefficient of 1. The effects of GLU on the solubility of PXM were also 
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investigated and this was achieved by the addition of an excess of PXM to 10 mL buffer (pH 1.2) 
containing GLU at 1, 5, 10 and 15 % w/v.  
 
2.9. Dissolution studies 
USP dissolution apparatus I (DT700, ERWEKA, Heusenstamm, Germany) was used to monitor the 
dissolution profiles of PXM, PXM-GLU PMs and spray-dried solid dispersions. All formulations 
for the dissolution process contained the same amount of PXM (20 mg of PXM content was used 
regardless of the carrier quantity). The powder samples, after weighing, were introduced into the 
dissolution basket. Circular paper discs were used to cover the base of the baskets. This was to 
prevent the drug powder falling through the bottom pores. The dissolution medium was at pH 1.2 
(900 mL) equilibrated to 37 °C ± 0.5 °C with the baskets rotated at 50 rpm. Samples were 
withdrawn at selected time intervals (5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 105 and 120 min) 
using a peristaltic pump. The concentrations of PXM in the samples were determined by UV 
spectrophotometer at 333 nm. All dissolution tests were carried out in triplicate. 
 
2.10. Dissolution parameters 
As an independent metric, the mean percentage of drug dissolved in the first 10 min (Q10min) and 30 
min (Q30min) were used to represent the dissolution rate from various preparations. The dissolution 
efficiency (DE) of a pharmaceutical dosage form is defined as the area under the dissolution curve 
up to the time, t, expressed as the percentage of the area of the rectangle [51] as detailed elsewhere 
[52, 53]. 
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Another approach to obtain a parameter that describes the dissolution rate is the mean dissolution 
time (MDT). This parameter is the most likely time taken for a molecule to be dissolved from a 
solid dosage form. In other words, MDT is the mean time for the drug to dissolve under in vitro 
dissolution conditions and is calculated using the following equation: 
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where j is the sample number, tj is the midpoint of the jth time period (calculated with ((t + t-1)/2) 
and Mj is the additional amount of drug dissolved between tj and t-1. 
 
The mean dissolution rate (MDR) can be calculated according to the following equations: 
MDR (%min
-1
) = 
n
tM
n
j
j


1
/
   
where n is the number of dissolution sample times, t is the time at the midpoint between t and t-1 
(easily calculated with [t + (t-1)/2]. 
 
2.11. Similarity factor 
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Similarity between the drug release profiles was determined using similarity factor f2 
according to the equation below [54-57]  
         {[  
 
 
∑  (     )
 
 
   
]
    
     } 
where n is the number of pull points for tested samples;    is the optional weight factor;    is 
the reference assay at time point t;    is the test assay at time point t. 
Similarity factor was calculated using the drug release profile of the untreated piroxicam as 
the reference. f2 values ranging from 50-100 indicate similarity between the two profiles. The 
closer the f2 value is to 100, the more similar or identical the release profiles. Values of f2 less 
than 50 indicate dissimilarity between two dissolution profiles [58, 59]. 
 
2.12. Triboelectric assessment of spray dried solid dispersions 
The charge properties of powders were analysed using a recent novel approach developed at the in 
the Wolfson Centre at the University of Greenwich. In brief, a triboelectric device electrostatic 
inductive sensor was used to investigate the triboelectrification of powders under investigation [48]. 
Such novel method allows the detection and measurement of charge distribution on the charge sign 
basis in a population of particles. The experimental apparatus consists of a single non-contact 
electrostatic inductive sensor (probe), a charge amplifier unit, a national instrument (NI) data 
acquisition equipment and personal computer for data recording and processing. A sample of each 
powder was fed in the cylindrical sensor with the help of vibratory feeder and conveyed toward the 
sensor by gravity in a vertical direction. Special care was taken by considering the adhesion 
property of particles with the wall of the sensor. After each experiment, the inner tube was replaced 
in order to remove any deposits, impurities or surface charge that may have been present on the 
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surface from a previous test. A fresh sample was used for each test experiment. Each sample was 
analysed six times (humidity and temperature controlled laboratory: 50% RH, 22 ºC). A typical 
example of processed charge signal obtained as a result of the untreated PXM particles moving 
through the sensor using vibratory orifice feeder under gravity is shown in Figure 1b. The direction 
of each peak shows the polarity of charged particles and amplitude from baseline and represents the 
amount of charge on moving particle. The positive charge is the sum of positive charges whereas 
the negative charge is the sum of negative charges. The net charge is the sum of positive charges 
and negative charges. The charge–to–mass ratio (CMR or charge density) was defined as the charge 
(negative charge for N–CMR, positive charge for P–CMR, net charge for net–CMR) per unit mass, 
in nC/g. 
 
3. RESULTS AND DISCUSSION 
Untreated PXM showed a DE of only 21.2 % over the 120 min interval (Table 1) demonstrating the 
reported poor solubility of PXM, which in turn affects its bioavailability. PXM is a drug 
administered via the oral route and it will have to pass through the first pass metabolic pathway, 
which further lowers its bioavailability. In order to achieve the desired therapeutic effect a high 
dose of the drug will have to be administered [22]. The poor dissolution characteristics of PXM 
may be due to poor wettability, where the dissolution media is unable to spread efficiently over the 
solid surfaces to bring about dissolution [29]. In addition, agglomeration of the drug particles could 
also limit solubility. The results from the spray-dried PXM and PMs indicated no significant 
difference in PXM dissolution regardless of PXM:GLU ratio (Figure 2a, Table 1) . In order words, 
the dissolution of the spray-dried PXM and the PM over the 120 min interval was similar to that of 
the untreated PXM (f2 = 74-93). However, when the untreated PXM was mixed with spray-dried 
GLU in the ratios 1:1, 1:2 and 2:1 (Figure 2b), the results of the 1:1 and 1:2 PMs showed DE to 
increase from 21.2 % as observed in untreated PXM to 33.2 % and 38.0 %, respectively. f2 values 
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using the untreated PXM as the reference showed dissimilarity to occur for the 1:1 and 1:2 
ratios (f2 = 46 and 39 respectively) thereby confirming the DE observations. These results 
showed that, in contrast to commercial GLU, mixing spray-dried GLU with PXM could enhance the 
dissolution of PXM. This may potentially be as a result of the change in morphology in the SEM 
images (Figure 3 and supplementary materials figure 1) of the spray dried GLU (smaller and less 
crystalline) and how the PXM may have attached on to them. This however was not true for the 2:1 
PXM and spray-dried GLU (f2 = 70). This sample had a DE value lower (DE120min of 16.4 %) than 
that of the untreated PXM (DE120min of 21 %) (Table 1). This may be due to the increased content of 
PXM in the formulation. 
Generally, fine particulates tend to charge negatively, whereas large particles tend to charge 
positively. Lacks and Levandovsky, 2007 [60] provided a hypothetical mechanism for particle size 
dependent charging. Assuming that the surface density of trapped electrons is initially the same on 
all particles, it has been argued that the collisions allow electrons trapped in high-energy states on 
one particle to transfer to the vacant low-energy states on another particle. This has been recently 
discussed in a review [61]. Triboelectric charge analyses showed that all materials investigated 
demonstrated bipolar charge behaviour, i.e., contained both electropositive and electronegative 
charge particles. Untreated PXM showed an overall electronegative charge density (net-CMR = - 
3.8 ± 0.9 nC/g) (Figure 4a). Such charging may result in several problems attributed to particle 
agglomeration, segregation and/or material adhesion on the processing equipment. In contrast, 
untreated GLU showed a very slight tendency towards electropositive charge (net-CMR = 0.5 ± 0.4 
nC/g) (Figure 4b). As seen in Figures 4a and b, PXM demonstrated a considerably higher absolute 
charge than GLU carrier. This may be due to differences in the inherent charging properties 
between PXM and GLU as well as the small size of PXM in comparison to GLU (Supplementary 
materials table 1) as it is known that electrostatic forces increase when particle size is decreased 
[16]. Both the electronegative charge density of PXM and the electropositive charge density of 
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GLU increased following spray drying (~ 2.0 fold-increase in the case of PXM drug ~ 5.9 fold-
increase in the case of GLU carrier) (Figures 4a, b). Triboelectric charge analyses showed spray 
dried PXM:GLU solid dispersions to have considerably lower charge density (-0.1 ± 0.1 – 0.3 ± 0.4 
nC/g, p > 0.05) than untreated PXM (- 3.8 ± 0.9 nC/g) and untreated GLU (0.5 ± 0.4 nC/g) (Figure 
5a). This shows the spray drying method applied reduced the charge of pure PXM and thus 
improves powder handling. 
Figure 5b shows the dissolution of spray-dried PXM and GLU (samples A - C) and the results show 
an enhancement in dissolution as compared to the untreated PXM. The increase in dissolution of the 
spray dried solid dispersion samples is likely due to the formation of small particle sizes, increased 
surface area and potentially reduced inter-particle cohesive forces as indicated by a net charge 
density of less than 0.4 nC/g (Figure 5a). SEM images (Figure 3 and supplementary materials table 
1) showed the appearance of the spray-dried samples to be very different from that of the parent 
drug and carrier. The spray drying process yielded spherical particles of around 2.5 µm but showed 
some agglomeration in Sample A, B and C with sample B showing some of the needle-like 
characteristics of PXM form II [62]. The needle form of PXM may have contributed to the poor 
dissolution of sample B as it has been reported that the form II PXM polymorph is less soluble than 
the Form I polymorph [63]. However, this was in contrast to the observations by other researchers 
who report an increase in solubility with the Form II polymorph [64, 65]. This contrasting 
difference may be due to differences in in the preparation method as well as the contribution 
of the polymorphic form to the solubility. Lai et al. [65] reasoned that the cavitation forces as 
well as the collision and shear forces during the homogenising they conducted determines the 
breakdown of drug particles to the nanometre range. They deduced further that these high 
energetic forces can also induce a change in the crystal structure and/or partial or total 
amorphisation of the sample, which could cause further enhancement in solubility[66]. 
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The dissolution results suggest that when PXM and GLU were spray-dried together, the 2:1 ratio 
(sample C) was the best in achieving the optimum level of dissolution enhancement. Sample C 
increased the dissolution of PXM by over 30 % in comparison to untreated PXM. Samples A - C 
(DE120min of 31- 57 %) all had improved dissolution efficiency over that of the untreated PXM 
(DE120min of 21 %). 
With regards to solubility, Table 2 shows untreated PXM to have a solubility of 20.7 mg/L. Spray-
dried PXM had a solubility of 17.7 mg/L which explained why the spray drying process did not 
improve dissolution. When the solubility tests were conducted with PXM in the presence of GLU at 
different concentrations, the solution containing 1 % w/v GLU had a solubility of 17.4 mg/L. This 
was also lower than the untreated PXM, which had a solubility of 20.7 mg/L. The solution 
containing 5 % w/v GLU also had solubility (20.1 %) slightly lower than that of the untreated PXM, 
however, this was an improvement from the 1 % w/v GLU. The solutions containing 10 % w/v and 
15 % w/v GLU both experienced solubility enhancement in comparison to that of the untreated 
PXM (20.7 %) with solubilities of 22.8 and 23.4 % respectively. The results therefore suggested 
that solubility could be improved by increasing the proportion of GLU in the solutions. However, 
the same conclusion could not be made regarding the results from the dissolution test as there was 
no correlation (Table 1). Al-Hamidi et al  2010 [3] concluded that an improvement in dissolution 
rate cannot be correlated to solubility and that parameters such as particle size, type of polymorph 
and hydrophobicity of particle surfaces are responsible for enhancement in dissolution. 
 Untreated PXM had a melting point of 201.53 ˚C signifying the form I PXM polymorph 
(Supplementary materials figure 2) [67]. However after spray drying, the DSC scan of spray-dried 
PXM exhibited two peaks; one at 196.47 ˚C and the other at 199.72˚C. This may be due to the fact 
that the spray drying process led to the re-crystallization of some PXM molecules in the Form II 
(lower melting point) polymorph of PXM [63]. This observation can be confirmed in the SEM 
image of spray-dried PXM (Supplementary materials figure 1) as needle-shaped PXM particles that 
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are characteristic of Form II PXM were also observed [68]. GLU appears as a single endothermic 
peak on the DSC trace (Supplementary materials figure 2) with a melting point at 210.27 ˚C. After 
spray drying however, it seems the characteristics of GLU were altered with the spray-dried GLU 
showing two distinct endothermic peaks on the DSC scans different from the peak observed from 
the untreated GLU. After further investigation, it was noticed that the untreated GLU DSC trace had 
a shoulder at the position of 222 - 225 ˚C. This was around the same position where the new peak 
appeared in spray-dried GLU and this suggests that the GLU also underwent some physical changes 
after spray drying. The DSC traces of the PM showed the PXM and GLU peaks to overlap 
(Supplementary materials figure 3). The melting points of the two materials are similar making the 
resultant peak of the PM to merge. It was observed that the intensity of the peaks varied as the ratio 
of each material varied in proportion. The DSC traces where PXM was mixed with SD GLU, 
(Supplementary materials figure 4), showed an overlap between PXM and GLU. The phenomenon 
was also seen in the DSC traces of the spray-dried formulations, Figure 6a, where peaks 
overlapping and changes in peak intensities with respect to the drug:carrier ratio were observed.  
The intense yellow colour observed in spray-dried Samples A - C has been attributed to the 
presence of amorphous PXM and this could be attributed to zwitterionic PXM molecules which are 
formed by an inter-molecular proton transfer in the amorphous form of the drug [69]. This was also 
confirmed by the low intensity of XRPD peaks for samples A-C. This indicates that the spray 
drying process in the presence of glucosamine HCl can induce some amorphous PXM in the 
samples. The XRPD diffractograms of PXM (Supplementary material figure 5) exhibited 
characteristic peaks at 8.64˚, 14.51˚, 17.70˚, 21.71 and 27.72˚ on the 2  scale which is similar to 
reported peak positions observed in the cubic Form I polymorph of PXM [68]. The XRPD 
diffractograms of spray-dried PXM was similar to that observed in untreated PXM indicating no 
change in the PXM as a result of the spray drying process. However, since the SEM images 
(Supplementary materials figure 1) and DSC (Supplementary materials figure 2) of spray-dried 
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PXM indicated the presence of needle shaped Form II PXM, it could be that the amount of Form II 
PXM recrystallized after spray drying was very small making it undetectable on the XRPD 
diffractograms. The characteristic peaks for GLU appeared at 16.73˚, 17.42˚, 27.19˚ and 31.94˚ 
[22]. However, after spray drying the position of these peaks changed. In addition, the peak 
intensities reduced significantly and this can be attributed to the process of spray drying. The 
significant reduction in the peak intensity of samples A-C was also attributed to the spray drying 
process (Figure 6b). This phenomenon has been observed by several authors where crystalline 
materials have reduced peak intensities or become amorphous after the spray drying process 
[70, 71]. 
 
4. CONCLUSIONS 
This study showed that spray-drying PXM alone was not sufficient to enhance the dissolution or 
solubility of PXM. This may be attributed to increased cohesive forces between spray dried PXM 
particles as compared to untreated PXM due to increased level of electrostatic charge. However, in 
the presence of a carrier such as GLU, spray drying proved to be effective at enhancing dissolution, 
therefore demonstrating glucosamine to be an efficient hydrophilic carrier for this process. This 
may be due to the relatively lack of cohesive electrostatic charge for spray dried solid dispersion 
particles allowing better particle wettability during dissolution.  The PXM underwent some 
polymorphic changes during the spray drying process and this was confirmed by the SEM images 
and DSC traces. The dissolution rate of PXM in the solid dispersions could be optimised by varying 
the drug:carrier ratio to achieve the desired rate. The charge results also proved GLU to improve the 
handling of PXM as it significantly reduced its charge in all the spray dried formulations. 
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Figure captions 
Figure 1. Schematic of experimental setup used in the determination of the formulations charge (a), 
a typical example of filtered data generated when untreated PXM particles are travelling through the 
sensor (b) 
Figure 2. Dissolution profile of PXM, spray-dried PXM and physical mixtures with different ratios 
of drug:carrier (a), dissolution profile of PXM, physical mixtures of PXM with spray-dried 
glucosamine (b) (SD, n=3) 
Figure 3. SEM images of spray dried solid dispersions of PXM: GLU in a 1:1 ratio (Sample A) (a), 
PXM: GLU in a 1:2 ratio (Sample B) (b) 
Figure 4. Positive charge-to-mass ratio (P-CMR), negative charge-to-mass ratio (N-CMR) and net 
charge-to-mass ratio (Net-CMR) for untreated PXM, spray dried PXM (a); untreated GLU and 
spray dried GLU (b) (SD, n=3) 
Figure 5. Positive charge-to-mass ratio (P-CMR), negative charge-to-mass ratio (N-CMR) and net 
charge-to-mass ratio (Net-CMR) for untreated PXM, untreated GLU and spray-dried solid 
dispersions (a) dissolution profiles of PXM and spray-dried solid dispersions (b) (SD, n=3) 
Figure 6. DSC thermograms of spray-dried solid dispersions of PXM: GLU in a 1:1 ratio (Sample 
A), PXM: GLU in a 1:2 ratio (Sample B) and PXM: GLU in a 2:1 ratio (Sample C) (a), XRPD 
patterns of spray-dried dispersions of PXM: GLU in a 1:1 ratio (Sample A), PXM: GLU in a 1:2 
ratio (Sample B) and PXM: GLU in a 2:1 ratio (Sample C) (b) 
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Tables 
Table 1. Effects of spray drying and carrier type on dissolution parameters of PXM (SD, n=3) 
Piroxicam 
(PXM):carrier 
Carrier DE120min (%) MDT(min) MDR(%min
-1
) Q10min (%) Q20min (%) Q30min (%) 
Untreated PXM - 21.2±0.5 7.8±0.6 0.18±0.02 8.5±0.4 11.9±0.2 17.5±1.8 
SD PXM - 20.6±5.8 7.7±0.8 0.2±0.08 10.3±1.2 15.4±2.5 19.0±4.9 
PM1:1  21.6±5.2 3.6±0.3 0.12±0.06 8.1±1.4 10.7±2.2 13.4±3.1 
PM1:2  21.2±0.5 6.98±0.2 0.17±0.01 8.5±1.0 12.3±0.5 17.4±0.8 
PM2:1  19.1±3.4 4.22±0.1 0.13±0.03 7.6±0.4 10.3±1.8 12.8±1.7 
1:1 SD GLU SD GLU 33.2±9.4 7.5±1.4 0.33±0.1 9.9±0.7 21.1±4.7 27.5±8.1 
1:2 SD GLU SD GLU 38.0±10.3 6.8±1.5 0.37±0.1 13.1±2.4 22.4±8.5 29.6±11.1 
2:1 SD GLU SD GLU 16.4±2.0 4.8±0.4 0.12±0.01 7.4±0.04 10.1±0.2 12.4±0.5 
Sample A (1:1)  38.9±3.8 5.6±1.7 0.38±0.10 26.3±3.2 31.7±5.7 37.8±6.8 
Sample B (1:2)  31.1±3.4 3.7±0.7 0.25±0.05 15.3±1.3 19.9±2.5 22.2±3.4 
Sample C (2:1)  56.7±4.7 6.0±2.6 0.53±0.13 25.4±3.6 32.0±2.9 43.6±7.2 
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Table 2. Solubility of PXM in the formulations. PXM in the presence of a carrier at different 
concentrations and PXM before and after spray drying (SD, n=3). 
Samples Amount of drug in solution (mg/L) 
Sample A (1:1) 32.6 ± 1.8 
Sample B (1:2) 15.5 ± 1.6 
Sample C (2:1) 19.5 ± 1.3 
Untreated PXM 20.7 ± 0.9 
Spray-dried PXM 17.7 ± 1.2 
1% GLU 17.4 ± 0.6 
5% GLU 20.1 ± 0.5 
10% GLU 22.8 ± 0.7 
15% GLU 23.4 ± 0.5 
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Piroxicam (PXM) and glucosamine (GLU) spray dried solid dispersions 
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